Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-pointMeletios Α. Dimopoulos, A. Palumbo, MT Petrucci et al.|Haematologica|2015Cited by 30
PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMAGary Cook, María‐Victoria Mateos, Eyt Chan et al.|HemaSphere|2019Cited by 3
Prognostic impact of cytogenetic abnormalities in newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: A prospective analysis of 593 patientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|F1000Research|2010Cited by 0